What did @kristinastout actually say?
The short version: GLP-1 medications are better for people with significant appetite issues or heavy food cravings, while AOD 9604 is better suited for already-fit patients trying to reduce body fat. She also said she sometimes adds AOD 9604 when GLP-1 patients hit a weight loss plateau, but does not recommend starting both at the same time.
A few things stand out immediately. She calls GLP-1s "weight loss peptides," which is technically inaccurate framing. She refers to semaglutide and tirzepatide by garbled names, calling them "some of a good tide" and "chryseptic tide." Small point, but these are FDA-approved medications with specific clinical identities, and getting the names right matters when you're a medical professional advising a public audience. She also describes AOD 9604 as a "fat burning peptide" that "uses human growth hormone to target fat," which is an oversimplification that deserves closer inspection.
Does the science back this up?
For GLP-1 receptor agonists, the evidence is strong and well-documented. For AOD 9604, it is thin, dated, and largely unpublished in humans at meaningful doses.
Semaglutide's weight loss data is robust. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed an average body weight reduction of 14.9% over 68 weeks in non-diabetic adults. Tirzepatide data from the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed up to 22.5% body weight reduction at the highest dose. The mechanism she describes, delayed gastric emptying and insulin sensitization, is accurate, though incomplete. GLP-1 agonists also act on hypothalamic receptors to reduce appetite signaling, which is where the "food noise" reduction actually comes from. That part she got right.
AOD 9604 is a different story. It is a synthetic peptide fragment derived from the C-terminus of human growth hormone, specifically amino acids 177-191. The early animal studies from Heffernan et al. (2001, Molecular and Cellular Endocrinology) showed lipolytic activity in rodents. But the human clinical program, run by Metabolic Pharmaceuticals, failed to demonstrate statistically significant weight loss in phase 2 and phase 3 trials, which is why it never received FDA approval as an obesity drug. The FDA granted it GRAS status for food use, not therapeutic use. There are no peer-reviewed, placebo-controlled human trials showing AOD 9604 meaningfully reduces body fat at the doses used in wellness settings today.
What did they get wrong (or right)?
She got the GLP-1 mechanism largely right. The description of delayed gastric emptying, improved insulin sensitivity, and appetite suppression is consistent with the clinical literature. Recommending GLP-1s for patients with significant food cravings and higher weight loss goals is reasonable and evidence-aligned.
She got the AOD 9604 framing wrong in a meaningful way. Describing it as a proven "fat burning peptide" without disclosing that its human clinical trials failed is a significant omission for a medical professional speaking to nearly 15,000 viewers. Saying it "uses human growth hormone to target fat" is also misleading. AOD 9604 is a fragment of growth hormone, not growth hormone itself, and it does not stimulate IGF-1 or the growth-promoting pathways that full GH does. That distinction matters, especially for patients who might otherwise be concerned about growth hormone side effects.
Her claim that adding AOD 9604 can "break through that weight loss barrier" in GLP-1 patients has no clinical trial evidence behind it. That may be her clinical observation, but presenting it as a predictable therapeutic strategy to a mass audience without that caveat is a stretch.
What should you actually know?
GLP-1 receptor agonists are among the most studied weight loss interventions in modern medicine. The clinical evidence is real, replicable, and published in top-tier journals. If weight loss is your primary goal and your provider recommends a GLP-1, that recommendation has a strong evidence base behind it.
AOD 9604 is being sold and prescribed in medical spa settings based on animal data and a failed human drug development program. That does not mean it does nothing, but it does mean the confidence level for clinical claims about it should be much lower than for GLP-1s. Patients should ask any provider recommending AOD 9604 specifically what evidence they are drawing on, and whether the product is compounded, which carries its own regulatory and quality considerations.
Combining peptides or adding them to existing medication regimens without clinical trial data on the combination is an area where caution is warranted. No published safety or efficacy data exists for the GLP-1 plus AOD 9604 combination she describes.
Bottom line
This video is partially accurate on GLP-1s and significantly overconfident on AOD 9604. A licensed nurse practitioner has the legal authority to prescribe or recommend these compounds in many states, but legal authority and clinical evidence are not the same thing. Patients watching this should understand the difference between a drug with phase 3 trial data and a peptide that failed its own clinical development program before reaching approval.